Daniel H Solomon1, Kristine Ruppert2, Gail A Greendale3, Yinjuan Lian2, Faith Selzer1, Joel S Finkelstein4. 1. 1 Division of Rheumatology, Department of Orthopedic Surgery, Brigham and Women's Hospital , Boston, Massachusetts. 2. 2 Department of Epidemiology, University of Pittsburgh , Pittsburgh, Pennsylvania. 3. 3 Department of Medicine, University of California-Los Angeles , Los Angeles, California. 4. 4 Endocrinology Unity, Massachusetts General Hospital , Boston, Massachusetts.
Abstract
BACKGROUND: Medication utilization and costs increased over the last decade, but the effects of race/ethnicity have never been well studied in longitudinal data. We analyzed reports of prescription medication use to (1) identify trajectories of use and (2) determine predictors associated with a large increase in use. Specifically, variations in medication use by race/ethnicity were examined. METHODS: We analyzed the Study of Women's Health Across the Nation cohort with a median of 14 years of follow-up. Group-based trajectory models helped distinguish women with a low use of medications versus those with heavy use. Logistic regression was used to estimate the odds ratio (OR) for each racial/ethnic group associated with heavy use, controlling for potential baseline confounders. RESULTS: The 2,798 women sampled had a mean age of 46 years at baseline and the median number of medications at baseline was 2, increasing to 4 over the follow-up period. Trajectory models identified that 16% of participants demonstrated heavy use of medications, from a median of 5 at baseline to 10 medications at final follow-up. Regression models controlling for age, obesity, number of comorbid conditions, and pain found that Hispanic (OR = 0.085, 95% confidence interval [CI]: 0.037-0.20), Chinese (OR = 0.32, 95% CI: 0.16-0.63), Japanese (OR = 0.33, 95% CI: 0.17-0.64), and Black (OR = 0.79, 95% CI: 0.57-1.11) women had lower odds for heavy use compared with White women. CONCLUSIONS: Longitudinal medication use among women in Study of Women's Health Across the Nation (SWAN) differed by race/ethnicity with non-White women having a lower odds of heavy use.
BACKGROUND: Medication utilization and costs increased over the last decade, but the effects of race/ethnicity have never been well studied in longitudinal data. We analyzed reports of prescription medication use to (1) identify trajectories of use and (2) determine predictors associated with a large increase in use. Specifically, variations in medication use by race/ethnicity were examined. METHODS: We analyzed the Study of Women's Health Across the Nation cohort with a median of 14 years of follow-up. Group-based trajectory models helped distinguish women with a low use of medications versus those with heavy use. Logistic regression was used to estimate the odds ratio (OR) for each racial/ethnic group associated with heavy use, controlling for potential baseline confounders. RESULTS: The 2,798 women sampled had a mean age of 46 years at baseline and the median number of medications at baseline was 2, increasing to 4 over the follow-up period. Trajectory models identified that 16% of participants demonstrated heavy use of medications, from a median of 5 at baseline to 10 medications at final follow-up. Regression models controlling for age, obesity, number of comorbid conditions, and pain found that Hispanic (OR = 0.085, 95% confidence interval [CI]: 0.037-0.20), Chinese (OR = 0.32, 95% CI: 0.16-0.63), Japanese (OR = 0.33, 95% CI: 0.17-0.64), and Black (OR = 0.79, 95% CI: 0.57-1.11) women had lower odds for heavy use compared with White women. CONCLUSIONS: Longitudinal medication use among women in Study of Women's Health Across the Nation (SWAN) differed by race/ethnicity with non-White women having a lower odds of heavy use.
Authors: Wenjun Zhong; Hilal Maradit-Kremers; Jennifer L St Sauver; Barbara P Yawn; Jon O Ebbert; Véronique L Roger; Debra J Jacobson; Michaela E McGree; Scott M Brue; Walter A Rocca Journal: Mayo Clin Proc Date: 2013-06-19 Impact factor: 7.616
Authors: Jodi B Segal; Jeanne M Clark; Andrew D Shore; Francesca Dominici; Thomas Magnuson; Thomas M Richards; Jonathan P Weiner; Eric B Bass; Albert W Wu; Martin A Makary Journal: Obes Surg Date: 2009-12 Impact factor: 4.129
Authors: Dima M Qato; G Caleb Alexander; Rena M Conti; Michael Johnson; Phil Schumm; Stacy Tessler Lindau Journal: JAMA Date: 2008-12-24 Impact factor: 56.272
Authors: Thomas D Sequist; Garrett M Fitzmaurice; Richard Marshall; Shimon Shaykevich; Dana Gelb Safran; John Z Ayanian Journal: Arch Intern Med Date: 2008-06-09
Authors: Daniel H Solomon; Leah Santacroce; Alicia Colvin; Yinjuan Lian; Kristine Ruppert; Kazuki Yoshida Journal: Pharmacoepidemiol Drug Saf Date: 2021-09-21 Impact factor: 2.732